Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer

Joseph A. Sparano, Molin Wang, Fengmin Zhao, Vered Stearns, Silvana Martino, Jennifer A. Ligibel, Edith A. Perez, Tom Saphner, Antonio C. Wolff, George W. Sledge, William C. Wood, John Fetting, Nancy E. Davidson

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

BACKGROUND: Obesity has been associated with inferior outcomes in operable breast cancer, but the relation between body mass index (BMI) and outcomes by breast cancer subtype has not been previously evaluated. METHODS: The authors evaluated the relation between BMI and outcomes in 3 adjuvant trials coordinated by the Eastern Cooperative Oncology Group that included chemotherapy regimens with doxorubicin and cyclophosphamide, including E1199, E5188, and E3189. Results are expressed as hazard ratios (HRs) from Cox proportional hazards models (HR >1 indicates a worse outcome). All P values are 2-sided. RESULTS: When evaluated as a continuous variable in trial E1199, increasing BMI within the obese (BMI, ≥30 kg/m2) and overweight (BMI, 25-29.9 kg/m 2) ranges was associated with inferior outcomes in hormone receptor-positive, human epidermal growth receptor 2 (HER-2)/neu-negative disease for disease-free survival (DFS; P =.0006) and overall survival (OS; P =.0007), but not in HER-2/neu-overexpressing or triple-negative disease. When evaluated as a categorical variable, obesity was associated with inferior DFS (HR, 1.24; 95% confidence interval [CI], 1.06-1.46; P =.0008) and OS (HR, 1.37; 95% CI, 1.13-1.67; P =.002) in hormone receptor-positive disease, but not other subtypes. In a model including obesity, disease subtype, and their interaction, the interaction term was significant for OS (P =.02) and showed a strong trend for DFS (P =.07). Similar results were found in 2 other trials (E5188, E3189). CONCLUSIONS: In a clinical trial population that excluded patients with significant comorbidities, obesity was associated with inferior outcomes specifically in patients with hormone receptor-positive operable breast cancer treated with standard chemohormonal therapy.

Original languageEnglish (US)
Pages (from-to)5937-5946
Number of pages10
JournalCancer
Volume118
Issue number23
DOIs
StatePublished - Dec 1 2012

Fingerprint

Body Mass Index
Obesity
Hormones
Breast Neoplasms
ErbB-2 Receptor
Confidence Intervals
Growth
Proportional Hazards Models
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Comorbidity
Clinical Trials
Drug Therapy
Survival
Population
Therapeutics

Keywords

  • breast cancer
  • disparity
  • hormone receptor positive
  • obesity
  • prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sparano, J. A., Wang, M., Zhao, F., Stearns, V., Martino, S., Ligibel, J. A., ... Davidson, N. E. (2012). Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer, 118(23), 5937-5946. https://doi.org/10.1002/cncr.27527

Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. / Sparano, Joseph A.; Wang, Molin; Zhao, Fengmin; Stearns, Vered; Martino, Silvana; Ligibel, Jennifer A.; Perez, Edith A.; Saphner, Tom; Wolff, Antonio C.; Sledge, George W.; Wood, William C.; Fetting, John; Davidson, Nancy E.

In: Cancer, Vol. 118, No. 23, 01.12.2012, p. 5937-5946.

Research output: Contribution to journalArticle

Sparano, JA, Wang, M, Zhao, F, Stearns, V, Martino, S, Ligibel, JA, Perez, EA, Saphner, T, Wolff, AC, Sledge, GW, Wood, WC, Fetting, J & Davidson, NE 2012, 'Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer', Cancer, vol. 118, no. 23, pp. 5937-5946. https://doi.org/10.1002/cncr.27527
Sparano, Joseph A. ; Wang, Molin ; Zhao, Fengmin ; Stearns, Vered ; Martino, Silvana ; Ligibel, Jennifer A. ; Perez, Edith A. ; Saphner, Tom ; Wolff, Antonio C. ; Sledge, George W. ; Wood, William C. ; Fetting, John ; Davidson, Nancy E. / Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. In: Cancer. 2012 ; Vol. 118, No. 23. pp. 5937-5946.
@article{efb2e3bdc71e4918856a11767163d535,
title = "Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer",
abstract = "BACKGROUND: Obesity has been associated with inferior outcomes in operable breast cancer, but the relation between body mass index (BMI) and outcomes by breast cancer subtype has not been previously evaluated. METHODS: The authors evaluated the relation between BMI and outcomes in 3 adjuvant trials coordinated by the Eastern Cooperative Oncology Group that included chemotherapy regimens with doxorubicin and cyclophosphamide, including E1199, E5188, and E3189. Results are expressed as hazard ratios (HRs) from Cox proportional hazards models (HR >1 indicates a worse outcome). All P values are 2-sided. RESULTS: When evaluated as a continuous variable in trial E1199, increasing BMI within the obese (BMI, ≥30 kg/m2) and overweight (BMI, 25-29.9 kg/m 2) ranges was associated with inferior outcomes in hormone receptor-positive, human epidermal growth receptor 2 (HER-2)/neu-negative disease for disease-free survival (DFS; P =.0006) and overall survival (OS; P =.0007), but not in HER-2/neu-overexpressing or triple-negative disease. When evaluated as a categorical variable, obesity was associated with inferior DFS (HR, 1.24; 95{\%} confidence interval [CI], 1.06-1.46; P =.0008) and OS (HR, 1.37; 95{\%} CI, 1.13-1.67; P =.002) in hormone receptor-positive disease, but not other subtypes. In a model including obesity, disease subtype, and their interaction, the interaction term was significant for OS (P =.02) and showed a strong trend for DFS (P =.07). Similar results were found in 2 other trials (E5188, E3189). CONCLUSIONS: In a clinical trial population that excluded patients with significant comorbidities, obesity was associated with inferior outcomes specifically in patients with hormone receptor-positive operable breast cancer treated with standard chemohormonal therapy.",
keywords = "breast cancer, disparity, hormone receptor positive, obesity, prognosis",
author = "Sparano, {Joseph A.} and Molin Wang and Fengmin Zhao and Vered Stearns and Silvana Martino and Ligibel, {Jennifer A.} and Perez, {Edith A.} and Tom Saphner and Wolff, {Antonio C.} and Sledge, {George W.} and Wood, {William C.} and John Fetting and Davidson, {Nancy E.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1002/cncr.27527",
language = "English (US)",
volume = "118",
pages = "5937--5946",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",

}

TY - JOUR

T1 - Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer

AU - Sparano, Joseph A.

AU - Wang, Molin

AU - Zhao, Fengmin

AU - Stearns, Vered

AU - Martino, Silvana

AU - Ligibel, Jennifer A.

AU - Perez, Edith A.

AU - Saphner, Tom

AU - Wolff, Antonio C.

AU - Sledge, George W.

AU - Wood, William C.

AU - Fetting, John

AU - Davidson, Nancy E.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - BACKGROUND: Obesity has been associated with inferior outcomes in operable breast cancer, but the relation between body mass index (BMI) and outcomes by breast cancer subtype has not been previously evaluated. METHODS: The authors evaluated the relation between BMI and outcomes in 3 adjuvant trials coordinated by the Eastern Cooperative Oncology Group that included chemotherapy regimens with doxorubicin and cyclophosphamide, including E1199, E5188, and E3189. Results are expressed as hazard ratios (HRs) from Cox proportional hazards models (HR >1 indicates a worse outcome). All P values are 2-sided. RESULTS: When evaluated as a continuous variable in trial E1199, increasing BMI within the obese (BMI, ≥30 kg/m2) and overweight (BMI, 25-29.9 kg/m 2) ranges was associated with inferior outcomes in hormone receptor-positive, human epidermal growth receptor 2 (HER-2)/neu-negative disease for disease-free survival (DFS; P =.0006) and overall survival (OS; P =.0007), but not in HER-2/neu-overexpressing or triple-negative disease. When evaluated as a categorical variable, obesity was associated with inferior DFS (HR, 1.24; 95% confidence interval [CI], 1.06-1.46; P =.0008) and OS (HR, 1.37; 95% CI, 1.13-1.67; P =.002) in hormone receptor-positive disease, but not other subtypes. In a model including obesity, disease subtype, and their interaction, the interaction term was significant for OS (P =.02) and showed a strong trend for DFS (P =.07). Similar results were found in 2 other trials (E5188, E3189). CONCLUSIONS: In a clinical trial population that excluded patients with significant comorbidities, obesity was associated with inferior outcomes specifically in patients with hormone receptor-positive operable breast cancer treated with standard chemohormonal therapy.

AB - BACKGROUND: Obesity has been associated with inferior outcomes in operable breast cancer, but the relation between body mass index (BMI) and outcomes by breast cancer subtype has not been previously evaluated. METHODS: The authors evaluated the relation between BMI and outcomes in 3 adjuvant trials coordinated by the Eastern Cooperative Oncology Group that included chemotherapy regimens with doxorubicin and cyclophosphamide, including E1199, E5188, and E3189. Results are expressed as hazard ratios (HRs) from Cox proportional hazards models (HR >1 indicates a worse outcome). All P values are 2-sided. RESULTS: When evaluated as a continuous variable in trial E1199, increasing BMI within the obese (BMI, ≥30 kg/m2) and overweight (BMI, 25-29.9 kg/m 2) ranges was associated with inferior outcomes in hormone receptor-positive, human epidermal growth receptor 2 (HER-2)/neu-negative disease for disease-free survival (DFS; P =.0006) and overall survival (OS; P =.0007), but not in HER-2/neu-overexpressing or triple-negative disease. When evaluated as a categorical variable, obesity was associated with inferior DFS (HR, 1.24; 95% confidence interval [CI], 1.06-1.46; P =.0008) and OS (HR, 1.37; 95% CI, 1.13-1.67; P =.002) in hormone receptor-positive disease, but not other subtypes. In a model including obesity, disease subtype, and their interaction, the interaction term was significant for OS (P =.02) and showed a strong trend for DFS (P =.07). Similar results were found in 2 other trials (E5188, E3189). CONCLUSIONS: In a clinical trial population that excluded patients with significant comorbidities, obesity was associated with inferior outcomes specifically in patients with hormone receptor-positive operable breast cancer treated with standard chemohormonal therapy.

KW - breast cancer

KW - disparity

KW - hormone receptor positive

KW - obesity

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=84869507377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869507377&partnerID=8YFLogxK

U2 - 10.1002/cncr.27527

DO - 10.1002/cncr.27527

M3 - Article

VL - 118

SP - 5937

EP - 5946

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 23

ER -